Slide 1: AstraZeneca Q1 2015 Results
AstraZeneca What science can do AstraZeneca Q1 2015 Results
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: The preliminary announcement contains certain forward-looking statements with respect to the
Slide 3: Agenda
Agenda Pascal Soriot Overview Luke Miels Growth platforms Marc Dunoyer Finance Briggs Morrison Pipeline Pascal Soriot Closing 3
Slide 4: Q1 2015: Key achievements
Q1 2015: Key achievements • Continued strong pipeline newsflow – 13 NMEs in Phase III or Registration – Strategic collaboration with Celgene to develop MEDI4736 in haematology • Total Revenue $6.1bn, +1% – Growth platforms $3.4bn, +13% – Launches of Lynparza and Movantik/Moventig proceeding well – E
Slide 5: Q1 2015: Strategic progress continues
Q1 2015: Strategic progress continues Returning to growth On track to deliver 7-8 potential • Growth platforms +13%, 56% of Total Revenue NME submissions in 2015-2016 • Movantik/Moventig launch CAZ AVI (CEPH/BLI) serious infections cediranib (VEGFR) savolitinib (AZD6094, MET) Achieving scientific le
Slide 6: Q1 2015: Growth platforms deliver
Q1 2015: Growth platforms deliver Q1 2015 Growth $m % Total Revenue 6,057 1 Growth Platforms 3,404 13 Brilinta /Brilique 131 45 Diabetes 488 47 Respiratory 1,243 7 Emerging Markets 1,533 18 Japan 455 (2) Core EPS $1.08 (3) Total Revenue and Product Sales at actual exchange rates. Growth rates at con
Slide 7: Externalisation accelerates; immuno-oncology strengthens
Externalisation accelerates; immuno-oncology strengthens Daiichi Sankyo Movantik externalisation Celgene strategic collaboration • US co-commercialisation agreement • Leveraging Celgene’s unique strategic • Leveraging Daiichi Sankyo’s existing position in haematology therapy area presence and joint
Slide 8: Growth platforms
Growth platforms Luke Miels EVP Global Portfolio & Product Strategy and Corporate Affairs
Slide 9: Q1 2015: Growth platforms show substantial progress
Q1 2015: Growth platforms show substantial progress Q1 2015 ($m) Growth (%) Brilinta/Brilique 131 45 Diabetes 488 47 Respiratory 1,243 7 Emerging Markets 1,533 18 Japan 455 (2)* Oncology: Lynparza Product Sales $9m Product Sales at actual exchange rates. Growth rates at constant exchange rates (CER)
Slide 10: Brilinta/Brilique: Continued progress
Brilinta/Brilique: Continued progress $m 140 +45% 8 Est. ROW +33% 120 • Positive PEGASUS results presented at ACC: 23 EM +108% 100 Significant 15% reduction in major CV events in patients with history of heart attack 80 46 US +64% • PEGASUS regulatory submissions (US, EU) 60 40 • Continued growth; E
Slide 11: Brilinta/Brilique: Encouraging increase globally
Brilinta/Brilique: Encouraging increase globally US oral anti-platelet class market share EU market share (new-to-brand prescriptions NBRx) days on therapy/volume 10% 9% 9.2% 8% 9% 7% 8% 6% Market share 5% 7% 7.4% 4% 6% 3% 5% 2% 1% 4% 0% Feb-14 Feb-15 Feb-15 Jul-14 Aug-14 Aug-14 Sep-14 Nov-14 Dec-14
Slide 12: Diabetes: Fa(o)rxiga launch ongoing; promising Bydureon Pen uptake
Diabetes: Fa(o)rxiga launch ongoing; promising Bydureon Pen uptake $m +47% 500 16 Others +14% • Continued strong Fa(o)rxiga performance in 90 Byetta +19% 400 all markets 76 Fa(o)rxiga +531% 300 • Onglyza US demand lower. Growth in all other significant markets 123 Bydureon +58% 200 • Bydureon US fue
Slide 13: Fa(o)rxiga: ROW markets now ~1/2 of total Product Sales
Fa(o)rxiga: ROW markets now make up ~1/2 of total Product Sales with Europe leading US volume European launch uptake amongst innovative oral anti- (weekly prescriptions) diabetic medicines (SGLT-2 + DPP4) 35,000 TRx NRx NBRx 33,328 30,000 Market Share days on therapy (DOT) 25,000 20,000 15,000 14,38
Slide 14: Bydureon: Strong US uptake of new Pen; EU launch
Bydureon: Strong US uptake of new Pen; EU launch US Bydureon family New launches (new monthly prescriptions NRx) • Q1: Launched in the UK, Ireland, Germany, Bydureon Pen Bydureon Tray Sweden, Finland 40,000 35,000 • Upcoming launches: Japan, Spain, 30,000 Denmark, Norway, Romania, Bulgaria, 25,000 N
Slide 15: Respiratory: Franchise growing 7%; Symbicort stable
Respiratory: Franchise growing 7%; Symbicort stable Symbicort $m 1,400 • US: Q1 relatively stable despite formulary +7% change; market share now returned to slight 1,200 112 Others +54% growth 1,000 286 Pulmicort +17% • EU: Marginal volume increase offset by price impact from analogues 800 • Emergin
Slide 16: Respiratory: Emerging Markets opportunities
Respiratory: Emerging Markets opportunities Asthma COPD ~250,000 new cases each year ~2.5m new cases each year m m 25 30 25 20 20 15 15 10 10 5 5 0 0 China Russia Brazil China Russia Brazil Diagnosed - treated Diagnosed - untreated Undiagnosed Diagnosed - Treated Diagnosed - Untreated Undiagnosed So
Slide 17: Emerging Markets: Continued strong growth
Emerging Markets: Continued strong growth Emerging Markets 18% 14% • Broad-based growth 13% 11% 11% 8% – Respiratory +35% 4% – Diabetes +115% 2012 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 – Oncology +16% +12% China 28% 22% 23% 21% 17% 19% 19% • China estimated underlying demand growth about 18%
Slide 18: Japan: Continued positive demand for growth brands
Japan: Continued positive demand for growth brands Key growth brands Symbicort monthly volume market share (%) 70.0 ~35% Symbicort share -20% 60.0 50.0 40.0 Nexium ~26% market share +23% 30.0 20.0 10.0 Crestor ~41% market share +7% - $m 0 50 100 150 Symbicort Competitor 1 Competitor 2 Competitor 3 P
Slide 19: Launch products
Launch products Movantik/Moventig Lynparza Opioid-induced constipation BRCA-mutated advanced ovarian cancer • US launch March 2015 • Q1 2015 Product Sales $9m (~90% US) – Co-commercialisation with 700 Cumulative new US patient starts Daiichi Sankyo 600 500 • Ongoing launches in Nordic countries 400
Slide 20: Finance
Finance Marc Dunoyer Executive Director, Chief Financial Officer
Slide 21: Q1 2015: Finance headlines
Q1 2015: Finance headlines Performance fully supports reiterated guidance Externalisation important part of business model Continued investment in R&D underpinning the accelerating pipeline Core SG&A: Increased area of focus 21
Slide 22: Q1 2015: Profit & Loss
Q1 2015: Profit & Loss Q1 2015 Q1 2014 Growth % Total $m $m % Revenue Total Revenue 6,057 6,460 1 Product Sales 5,748 6,416 (3) Externalisation Revenue 309 44 n/m Core Cost of Sales (953) (1,193) (8) 16 Distribution (77) (72) 19 1 Core R&D (1,280) (1,098) 24 21 Core SG&A (2,368) (2,317) 10 39 Core T
Slide 23: Core SG&A: Increased area of focus
Core SG&A: Increased area of focus Investment peaked Q4 2014 Productivity programmes to accelerate $m 3,000 • Sales & marketing effectiveness 2,500 Fx* 2,000 • Savings across procurement, support functions & IT 1,500 1,000 • Further footprint optimisation 500 0 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 201
Slide 24: 2015 full-year guidance reiterated
2015 full-year guidance reiterated Total revenue Decline by mid single-digit percent Constant exchange rates Core EPS Increase by low single-digit percent The Company also provides the following non-guidance information related to currency sensitivity: Based on current exchange rates, total revenue
Slide 25: 2015 outlook
2015 outlook Reduce Core Accelerate SG&A in value externalisation & & percentage partnering Total revenue Decline by mid single-digit percent Constant exchange rates Core EPS Increase by low single-digit percent 25
Slide 26: Externalisation accelerating
Externalisation accelerating Daiichi Sankyo Movantik externalisation Celgene strategic collaboration • Upfront externalisation payment $200m • Upfront externalisation payment $450m • Subsequent sales-related in relation to MEDI4736 Externalisation Revenue up to $625m • Celgene to cover development c
Slide 27: Pipeline
Pipeline Briggs Morrison EVP Global Medicines Development & Chief Medical Officer
Slide 28: Q1 2015: Pipeline updates
Q1 2015: Pipeline updates Late-stage clinical update Regulatory update • Brilinta/Brilique positive Phase III PEGASUS • lesinurad submission acceptance (US) study in prior myocardial infarction • Brilinta/Brilique regulatory submission Phase III PEGASUS (US, EU) • PT003 positive top-line Phase III P
Slide 29: Recent Oncology meeting updates
Recent Oncology meeting updates American Assoc. for Cancer Research European Lung Cancer Conference 18-22 April 15-18 April • 62 abstracts including data on OX40, CD73, • Updated PFS for AZD9291 (NSCLC; AURA PI3K, AKT, mTOR, EGFR, SERD & PARP study) of 13.5 months in T790M, 80mg cohort, independent
Slide 30: Oncology: Key milestones through 2015
Oncology: Key milestones through 2015 American Society of Clinical Oncology Data highlights (ASCO) 29 May – 2 June • MEDI4736 AZD9291 – Phase I/II update • Phase II (2L NSCLC EGFRm/T790M) selumetinib (NSCLC and SCCHN) • Phase III SUMIT (metastatic uveal melanoma) • Phase II (paediatric neurofibrom
Slide 31: Late-stage pipeline: Key news flow through 2015
Late-stage pipeline: Key news flow through 2015 Compound Indication Potential milestone brodalumab1 psoriasis Regulatory submission PT003 (LAMA/LABA) COPD Phase III results Regulatory submission RIA anifrolumab lupus/SLE Phase II presentation lesinurad gout Regulatory submission CVMD Brilinta/Br
Slide 32: Closing
Closing Pascal Soriot Executive Director, Chief Executive Officer
Slide 33: Q1 2015: Key achievements
Q1 2015: Key achievements • Continued strong pipeline newsflow – 13 NMEs in Phase III or Registration – Strategic collaboration with Celgene to develop MEDI4736 in haematology • Total Revenue $6.1bn, +1% – Growth platforms $3.4bn, +13% – Launches of Lynparza and Movantik/Moventig proceeding well – E
Slide 34: Q&A
Q&A Pascal Soriot, Executive Director, Chief Executive Officer (Moderator) Marc Dunoyer, Executive Director, Chief Financial Officer Briggs Morrison, EVP Global Medicines Development & Chief Medical Officer Luke Miels, EVP Global Portfolio & Product Strategy and Corporate Affairs Please press *1 on